Circulating Cancer Biomarkers: Progress, Challenges and Opportunities
Deadline for manuscript submissions: 31 May 2024 | Viewed by 1254
Interests: esophageal cancer; development therapeutics; precision medicine; lung cancer; surveillance; early detection; disease monitoring; treatment response and immunotherapy
Special Issues, Collections and Topics in MDPI journals
Cancer is a leading cause of morbidity and mortality worldwide. Therefore, there is an urgent to identify, develop and validate novel non-invasive cancer biomarkers for screening and early detection, risk assessment, accurate diagnosis, patient prognosis, prediction of response to therapy, and cancer surveillance and monitoring response. These markers can also be used as targets for future cancer treatments.
Currently, cancer biomarkers can be measured in both tissue and liquid biopsy and may include germline or somatic genetic variants, transcriptional changes, epigenetic, proteomic and metabolomic signatures. In recent years, tremendous advances have been made in high throughput ‘omics’ approaches, including techniques such as next-generation sequencing or methods to study circulating tumor DNA/RNA, exosomes or proteins. This progress has been most visible in the development of minimally invasive blood-based approaches to comprehensively identify and characterize molecular alterations from heterogeneous primary tumors, while simultaneously capturing tumor load and metastasis. However, challenges remain with developing new liquid biopsy biomarkers with high sensitivity, specificity, and positive predictive value, which is now being addressed through improved technology and bioinformatics.
This Special Issue will highlight the role of circulating biomarkers on cancer care, by improving cancer patient diagnoses, management, and outcomes. We welcome both original research or review articles covering basic and clinical research studies aligned with the aforementioned topic.
Dr. Ali Zaidi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- liquid biopsy
- cancer biomarkers
- precision oncology
- early detection
- response monitoring
- predicting treatment response
- risk stratification
- screening and surveillance
- DNA methylation